Mifepristone
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Weight-Gain Prevention
Conditions
Weight-Gain Prevention
Trial Timeline
Mar 1, 2007 → Jul 1, 2007
NCT ID
NCT00455442About Mifepristone
Mifepristone is a phase 2 stage product being developed by Eli Lilly for Weight-Gain Prevention. The current trial status is completed. This product is registered under clinical trial identifier NCT00455442. Target conditions include Weight-Gain Prevention.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00455442 | Phase 2 | Completed |